Incorporating Economic Evaluations Into Decision-Making
- 1 July 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medical Care
- Vol. 43 (7), 15
- https://doi.org/10.1097/01.mlr.0000170002.90751.1a
Abstract
The Drug Quality and Therapeutics Committee (DQTC) and the Canadian Expert Drug Assessment Committee (CEDAC) make reimbursement recommendations to publicly funded outpatient drug plans in Ontario and Canada respectively. In this article, the organization and decision-making processes of these committees are described. Issues associated with these committees such as potential biases associated with pharmaceutical company submissions, transparency, restricted access programs, conditional listing, and price negotiation are discussed.Keywords
This publication has 4 references indexed in Scilit:
- Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosisBMJ, 2003
- The role of databases in drug postmarketing surveillancePharmacoepidemiology and Drug Safety, 2001
- Problems With the Interpretation of Pharmacoeconomic AnalysesJAMA, 2000
- Guidelines for Economic Analysis of Pharmaceutical ProductsPharmacoEconomics, 1993